Adipose modulation of high-density lipoprotein cholesterol: Implications for obesity, high-density lipoprotein metabolism, and cardiovascular disease

Circulation

Volumn 124, Issue 15, 2011, Pages 1602-1605

  McGillicuddy, Fiona C ^a   Reilly, Muredach P ^b   Rader, Daniel J ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; HUMAN; LIPOPROTEIN METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ADIPOSE TISSUE; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; OBESITY;

EID: 80053935086     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.058453     Document Type: Review

References (20)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
2. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92:42J-49J.
3. Robinson JG. Low high-density lipoprotein cholesterol and chronic disease risk marker or causal? J Am Coll Cardiol. 2010;55:2855-2857.
4. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122. (Pubitemid 350146106)
5. NHLBI Communications Office. NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. NIH News. May 26, 2011. http://www.nih.gov/news/health/ may2011/nhlbi-26.htm. Accessed August 22, 2011.
6. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
7. Young SG, Fielding CJ. The ABCs of cholesterol efflux. Nat Genet. 1999;22:316-318. (Pubitemid 29369515)
8. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712-719. (Pubitemid 36566157)
9. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest. 2001;108:1315-1320. (Pubitemid 33107759)
10. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-1342. (Pubitemid 40629053)
11. Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, Van Berkel TJ, Parks JS, Staels B, Rothblat GH, Fievet C, Hayden MR. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 2006;114:1301-1309. (Pubitemid 44402056)
12. Karasinska JM, Rinninger F, Lutjohann D, Ruddle P, Franciosi S, Kruit JK, Singaraja RR, Hirsch-Reinshagen V, Fan J, Brunham LR, Bissada N, Ramakrishnan R, Wellington CL, Parks JS, Hayden MR. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci. 2009;29:3579-3589.
13. Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation. 2011;124:1663-1672.
14. Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 2010;121:1347-1355.
15. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769. (Pubitemid 34655342)
16. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-1119. (Pubitemid 40629025)
17. Park KH, Shin DG, Kim JR, Hong JH, Cho KH. The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med. 2010;25:129-136.
18. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135-1145.
19. Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta. 2006;365:119-124. (Pubitemid 43196426)
20. Toh SA, Millar JS, Billheimer J, Fuki I, Naik SU, Macphee C, Walker M, Rader DJ. PPARgamma activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. Biochem Pharmacol. 2011;81:934-941.